Table 1.
Treatment response to carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma
| Carfilzomib | ||||||||
|---|---|---|---|---|---|---|---|---|
| 15 mg/m2 (n = 4) | 20 mg/m2 (n = 6) | 20/27 mg/m2 (n = 40) | Total (N = 50) | |||||
| No. of patients (%) | 95% CI | No. of patients (%) | 95% CI | No. of patients (%) | 95% CI | No. of patients (%) | 95% CI | |
| ORR (sCR + CR + VGPR + PR) | 1 (25.0) | 4.6, 69.9 | 0 (0.0) | 0.0, 39.0 | 9 (22.5) | 12.3, 37.5 | 10 (20.0) | 11.2, 33.0 |
| sCR | 0 | 0.0, 49.0 | 0 | 0.0, 39.0 | 1 (2.5) | 0.4, 12.9 | 1 (2.0) | 0.4, 10.5 |
| CR | 0 | 0.0, 49.0 | 0 | 0.0, 39.0 | 0 | 0.0, 8.8 | 0 | 0.0, 7.1 |
| VGPR | 0 | 0.0, 49.0 | 0 | 0.0, 39.0 | 2 (5.0) | 1.4, 16.5 | 2 (4.0) | 1.1, 13.5 |
| PR | 1 (25.0) | 4.6, 69.9 | 0 | 0.0, 39.0 | 6 (15.0) | 7.1, 29.1 | 7 (14.0) | 7.0, 26.2 |
| SD | 1 (25.0) | 4.6, 69.9 | 3 (50.0) | 18.8, 81.2 | 18 (45.0) | 30.7, 60.2 | 22 (44.0) | 31.2, 57.7 |
| PD | 0 | 0.0, 49.0 | 1 (16.7) | 3.0, 56.4 | 9 (22.5) | 12.3, 37.5 | 10 (20.0) | 11.2, 33.0 |
| NE | 2 (50.0) | 15.0, 85.0 | 2 (33.3) | 9.7, 70.0 | 4 (10.0) | 4.0, 23.1 | 8 (16.0) | 8.3, 28.5 |
| CBR (sCR + CR + VGPR + PR + MR) | 1 (25.0) | 4.6, 69.9 | 2 (33.3) | 9.7, 70.0 | 13 (32.5) | 20.1, 48.0 | 16 (32.0) | 20.8, 45.8 |
CBR, clinical benefit rate; CI, confidence interval; CR, complete response; MR, minimal response; NE, not evaluable; ORR, overall response rate; PD, progressive disease; PR, partial response; sCR, stringent complete response; SD, stable disease; VGPR, very good partial response.